Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure

Cardiology (Switzerland)

Volumn 122, Issue 3, 2012, Pages 158-166

  Manzano Fernandez S ^a   Januzzi, J L ^b   Pastor Perez F J ^a   Bonaque Gonzalez J C ^a   Boronat Garcia, M ^a   Pascual Figal, D A ^a   Montalban Larrea, S ^a   Navarro Penalver M ^a   Andreu Cayuelas, J M ^a   Valdes M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Heart failure; Monitoring; Prognosis; ST2

Indexed keywords

SOLUBLE INTERLEUKIN 2 RECEPTOR;

ACCURACY; ACUTE HEART FAILURE; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STRATIFIED SAMPLE; VITAL STATISTICS;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; ROC CURVE;

EID: 84864109759     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000338800     Document Type: Article

References (34)

1. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50: 607-613. (Pubitemid 47199007)
2. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL: Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011; 107: 259-267.
3. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M: Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752-756. (Pubitemid 351573718)
4. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL: Soluble ST2, high-sensitivity troponin T-and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725.
5. Rehman SU, Mueller T, Januzzi JL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52: 1458-1465.
6. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL: Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009; 2: 311-319.
7. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL: Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008; 14: 732-738.
8. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416. (Pubitemid 40283098)
9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005. Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
10. Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T: Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009; 409: 33-40.
11. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA: Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 254-261.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
13. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172. (Pubitemid 351193639)
14. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259. (Pubitemid 44079340)
15. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ: Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55: 243-250.
16. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT: Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966. (Pubitemid 35424749)
17. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT: IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-1549. (Pubitemid 46871338)
18. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721-726. (Pubitemid 36222600)
19. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A: Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009; 54: 2174-2179.
20. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS: Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010; 160: 721-728.
21. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM: Nterminal pro-B-type natriuretic peptideguided treatment for chronic heart failure: results from the BATTLESCARRED (NTproBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60.
22. Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, Hulot JS, Thomas D, Piwowarska W, Komajda M: Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004; 25: 1788-1796. (Pubitemid 39330229)
23. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-391.
24. Bettencourt P, Januzzi JL Jr: Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am J Cardiol 2008; 101: 67-71.
25. Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordonez-Llanos J, Martinez P, Cinca J, Valdes M, Januzzi JL, Bayes-Genis A: Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008; 29: 1011-1018. (Pubitemid 351844674)
26. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, Pfeffer M, Rouleau JL, Stevenson LW: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 1623-1629. (Pubitemid 34494285)
27. van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr: Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006; 98: 386-390. (Pubitemid 44062449)
28. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41: 2010-2017. (Pubitemid 36677124)
29. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1,256 patients: the International Collaborative of NT-pro-BNP Study. Eur Heart J 2006; 27: 330-337. (Pubitemid 43100029)
30. Baggish AL, van Kimmenade RR, Januzzi JL Jr: Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. Am J Cardiol 2008; 101: 49-55.
31. Perna ER, Macin SM, Cimbaro Canella JP, Szyszko A, Franciosi V, Vargas MW, Bayol AP, Kriskovich JO, Medina F, Gonzalez AB, Brizuela M: Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure. J Heart Lung Transplant 2006; 25: 1230-1240. (Pubitemid 44528293)
32. Peacock WF, De MT, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH: Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-2126. (Pubitemid 351679598)
33. Mueller C: Risk stratification in acute decompensated heart failure: the role of cardiac troponin. Nat Clin Pract Cardiovasc Med 2008; 5: 680-681.
34. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM: Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010; 56: 1071-1078.